STUDIES TO EVALUATE THE POTENTIAL FOR ENVIRONMENTAL&THERAPEUTIC AGENTS TO INDUCE IMMUNOTOXICITY - In vivo

NTP PAC混合物评估计划（PAC-MAP）提供了一个框架，用于评估单个多环芳香族化合物（PAC），定义的PAC混合物和复杂的含PAC环境样品的广度，使用体外/短期体内测试电池，包括广泛的端点。某些PAC与广泛的毒性（致癌性、免疫毒性、生殖和发育毒性、神经毒性）和一系列复杂的作用机制相关。特别是，许多PAC与体液免疫功能抑制有关，免疫毒性已被确定为估计PAC致癌潜力的信息参数。作为预测混合物效应的潜在测试组合的一部分，我们检查了13种单独PAC和3种混合物调节抗原特异性抗体应答和影响骨髓细胞学的潜力。 2021财年未启动体内免疫毒理学研究，工作重点是数据分析和报告/存档之前合同年度进行的研究。 BRT在2021财年为各个PAC-MAP免疫毒性研究提供了4份最终报告和3份报告草案。 BRT完成了另外5份报告，并提供了2份PAC MAP化学品免疫病理学研究的报告草案。 磷酸三（氯丙基）酯（TCPP）发育免疫毒理学研究的最终报告也于2021财年完成。 此外，BRT关闭了MPEP的免疫病理学研究，NTP审查了免疫毒性和抗病性研究的报告草案。

The NTP PAC Mixtures Assessment Program (PAC-MAP) provides the framework for assessing a breadth of individual polycyclic aromatic compounds (PACs), defined PAC mixtures, and complex PAC-containing environmental samples using an in vitro/short-term in vivo testing battery that includes a broad spectrum of endpoints. Select PACs have been associated with a wide range of toxicities (carcinogenicity, immunotoxicity, reproductive and developmental toxicity, neurotoxicity) and a complicated array of mechanisms of action. In particular, many PACs have been associated with suppression of humoral immune function and immunotoxicity has been identified as an informative parameter for estimating the carcinogenic potential of PACs. As part of the potential testing battery to predict mixture effects, we have examined the potential for 13 individual PACs and 3 mixtures to modulate the antigen specific antibody response and affect bone marrow cytology. No in vivo immunotoxicology studies were started in FY21 and efforts were focused on data analysis and reporting/archiving of studies conducted in previous contract years. BRT provided 4 final reports and 3 draft reports for individual PAC-MAP immunotoxicity studies in FY21. BRT completed an additional 5 reports and provided 2 draft reports for immunopathology studies of the PAC MAP chemicals. The final report for the developmental immunotoxicology studies on Tris (Chloropropyl) phosphate (TCPP) was also completed in FY21. In addition, BRT closed the immunopathology study for MPEP, and draft reports for the immunotoxicity and disease resistances studies were reviewed by the NTP.